Literature DB >> 21160824

Peroxisome proliferator-activated receptor γ and colorectal cancer.

Yun Dai1, Wei-Hong Wang.   

Abstract

Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily and ligand-activated transcription factors. PPARγ plays an important role in adipocyte differentiation, lipid storage and energy dissipation in adipose tissue, and is involved in the control of inflammatory reactions as well as in glucose metabolism through the improvement of insulin sensitivity. Growing evidence has demonstrated that activation of PPARγ has an antineoplastic effect in tumors, including colorectal cancer. High expression of PPARγ is detected in human colon cancer cell lines and adenocarcinoma. This review describes the molecular mechanisms by which PPARγ regulates tumorigenesis in colorectal cancer, and examines current clinical trials evaluating PPARγ agonists as therapeutic agents for colorectal cancer.

Entities:  

Keywords:  Colorectal cancer; Ligand; Peroxisome proliferator-activated receptors; Tumor suppression

Year:  2010        PMID: 21160824      PMCID: PMC2999174          DOI: 10.4251/wjgo.v2.i3.159

Source DB:  PubMed          Journal:  World J Gastrointest Oncol


  77 in total

Review 1.  Peroxisome proliferator-activated receptors: nuclear control of metabolism.

Authors:  B Desvergne; W Wahli
Journal:  Endocr Rev       Date:  1999-10       Impact factor: 19.871

Review 2.  The PPARs: from orphan receptors to drug discovery.

Authors:  T M Willson; P J Brown; D D Sternbach; B R Henke
Journal:  J Med Chem       Date:  2000-02-24       Impact factor: 7.446

Review 3.  Thiazolidinediones: a new class of antidiabetic drugs.

Authors:  C Day
Journal:  Diabet Med       Date:  1999-03       Impact factor: 4.359

4.  Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma.

Authors:  G D Demetri; C D Fletcher; E Mueller; P Sarraf; R Naujoks; N Campbell; B M Spiegelman; S Singer
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

5.  Frequent polymorphism of peroxisome proliferator activated receptor gamma gene in colorectal cancer containing wild-type K-ras gene.

Authors:  Shigeki Tomita; Hitoshi Kawamata; Johji Imura; Fumie Omotehara; Yoshihiko Ueda; Takahiro Fujimori
Journal:  Int J Mol Med       Date:  2002-05       Impact factor: 4.101

6.  Activation of peroxisome proliferator-activated receptor-gamma stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells.

Authors:  Teturou Satoh; Mitsuo Toyoda; Hideki Hoshino; Tsuyoshi Monden; Masanobu Yamada; Hiroyuki Shimizu; Kaoru Miyamoto; Masatomo Mori; Masanabu Yamada; Matsumoto Mori
Journal:  Oncogene       Date:  2002-03-28       Impact factor: 9.867

7.  Peroxisome proliferator-activated receptor gamma activation can regulate beta-catenin levels via a proteasome-mediated and adenomatous polyposis coli-independent pathway.

Authors:  Chandan Sharma; Anamika Pradeep; Lucas Wong; Ajay Rana; Basabi Rana
Journal:  J Biol Chem       Date:  2004-06-09       Impact factor: 5.157

8.  Rosiglitazone induces caveolin-1 by PPARgamma-dependent and PPRE-independent mechanisms: the role of EGF receptor signaling and its effect on cancer cell drug resistance.

Authors:  Lilach Tencer; Elke Burgermeister; Matthias P Ebert; Mordechai Liscovitch
Journal:  Anticancer Res       Date:  2008 Mar-Apr       Impact factor: 2.480

9.  Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal.

Authors:  L E Benjamin; D Golijanin; A Itin; D Pode; E Keshet
Journal:  J Clin Invest       Date:  1999-01       Impact factor: 14.808

10.  Synergistic Effects of PPARgamma Ligands and Retinoids in Cancer Treatment.

Authors:  Masahito Shimizu; Hisataka Moriwaki
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

View more
  13 in total

Review 1.  Mechanistic aspects of COX-2 expression in colorectal neoplasia.

Authors:  Dan A Dixon; Fernando F Blanco; Annalisa Bruno; Paola Patrignani
Journal:  Recent Results Cancer Res       Date:  2013

Review 2.  Acromegaly and Colorectal Neoplasm: An Update.

Authors:  Leandro Kasuki; Bernardo Maia; Mônica R Gadelha
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-20       Impact factor: 6.055

Review 3.  Emerging role of the β-catenin-PPARγ axis in the pathogenesis of colorectal cancer.

Authors:  Lina Sabatino; Massimo Pancione; Carolina Votino; Tommaso Colangelo; Angelo Lupo; Ettore Novellino; Antonio Lavecchia; Vittorio Colantuoni
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

4.  Short-chain fatty acids stimulate angiopoietin-like 4 synthesis in human colon adenocarcinoma cells by activating peroxisome proliferator-activated receptor γ.

Authors:  Sheril Alex; Katja Lange; Tom Amolo; Jeffrey S Grinstead; Anders K Haakonsson; Ewa Szalowska; Arjen Koppen; Karin Mudde; Daniëlle Haenen; Sa'ad Al-Lahham; Han Roelofsen; René Houtman; Bart van der Burg; Susanne Mandrup; Alexandre M J J Bonvin; Eric Kalkhoven; Michael Müller; Guido J Hooiveld; Sander Kersten
Journal:  Mol Cell Biol       Date:  2013-01-22       Impact factor: 4.272

5.  PPARs Signaling and Cancer in the Gastrointestinal System.

Authors:  Valerio Pazienza; Manlio Vinciguerra; Gianluigi Mazzoccoli
Journal:  PPAR Res       Date:  2012-09-17       Impact factor: 4.964

6.  The Role of PPARγ in the Transcriptional Control by Agonists and Antagonists.

Authors:  Tamotsu Tsukahara
Journal:  PPAR Res       Date:  2012-05-29       Impact factor: 4.964

7.  PPARs: Interference with Warburg' Effect and Clinical Anticancer Trials.

Authors:  Joseph Vamecq; Jean-Marie Colet; Jean Jacques Vanden Eynde; Gilbert Briand; Nicole Porchet; Stéphane Rocchi
Journal:  PPAR Res       Date:  2012-05-08       Impact factor: 4.964

Review 8.  Chemotherapy and chemoprevention by thiazolidinediones.

Authors:  Eleonore Fröhlich; Richard Wahl
Journal:  Biomed Res Int       Date:  2015-03-19       Impact factor: 3.411

9.  MultiNotch MS3 enables accurate, sensitive, and multiplexed detection of differential expression across cancer cell line proteomes.

Authors:  Graeme C McAlister; David P Nusinow; Mark P Jedrychowski; Martin Wühr; Edward L Huttlin; Brian K Erickson; Ramin Rad; Wilhelm Haas; Steven P Gygi
Journal:  Anal Chem       Date:  2014-07-03       Impact factor: 8.008

10.  FOXD3 is a tumor suppressor of colon cancer by inhibiting EGFR-Ras-Raf-MEK-ERK signal pathway.

Authors:  Kun Li; Qunfeng Guo; Jun Yang; Hui Chen; Kewen Hu; Juan Zhao; Shunxin Zheng; Xiufeng Pang; Sufang Zhou; Yongyan Dang; Lei Li
Journal:  Oncotarget       Date:  2017-01-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.